BRAF

Biomarkers

BRAF is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
BRAF p.V600K	Somatic Variant	10	23
BRAF rearrangements	Rearrangement	1	1
BRAF p.V600E	Somatic Variant	17	43
v::BRAF	Rearrangement	1	1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
EMA (2) FDA (2)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
EMA (1) FDA (1)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
EMA (4) FDA (4)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
EMA (1) FDA (1)	BRAF p.V600K	Melanoma	Trametinib
FDA (1)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
FDA (1)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib
EMA (2)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
EMA (1)	BRAF p.V600K	Melanoma	Dabrafenib
EMA (1)	BRAF p.V600K	Melanoma	Vemurafenib
FDA (1)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib
FDA (1)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
EMA (2) FDA (2)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
EMA (2) FDA (2)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
EMA (1) FDA (2)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
EMA (1) FDA (1)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
EMA (1) FDA (1)	BRAF p.V600E	Melanoma	Dabrafenib
EMA (4) FDA (4)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
EMA (2) FDA (2)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
FDA (2)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
FDA (2)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
EMA (1) FDA (2)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
EMA (1) FDA (1)	BRAF p.V600E	Melanoma	Trametinib
EMA (1) FDA (1)	BRAF p.V600E	Melanoma	Vemurafenib
FDA (1)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
FDA (1)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib
FDA (1)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib
FDA (1)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib